Karyopharm Expanded Access Program (KEAP) for selinexor

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development and subsequent commercialization of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. The Karyopharm Expanded Access Program (KEAP) aims to provide access to the unlicensed medicine selinexor to patients with Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma (adult and pediatric) and Peripheral T-Cell Lymphoma (adult and pediatric), who have exhausted all available treatment options and are ineligible for any open clinical trials with selinexor.

Caligor Coghlan (CalCog) is a specialty global pharmaceutical and services business dedicated to serving patients, the community and the healthcare industry. CalCog has compiled a team of experts in implementing global expanded access programs. CalCog will manage the KEAP on behalf of Karyopharm Therapeutics Inc.